{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T03:58:27Z","timestamp":1776484707691,"version":"3.51.2"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T00:00:00Z","timestamp":1725667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T00:00:00Z","timestamp":1725667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Natural Science Foundation of Shandong Province of China","award":["ZR2022QH297"],"award-info":[{"award-number":["ZR2022QH297"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82170123"],"award-info":[{"award-number":["82170123"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"DOI":"10.1186\/s13000-024-01544-8","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T09:02:30Z","timestamp":1725699750000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation: a case report, meta-analysis, and systematic review"],"prefix":"10.1186","volume":"19","author":[{"given":"You-yuan","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-fei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen-yu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-wei","family":"Lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-bin","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-yuan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan-fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-guang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,7]]},"reference":[{"issue":"7","key":"1544_CR1","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/j.bbmt.2019.02.016","volume":"25","author":"A Fujimoto","year":"2019","unstructured":"Fujimoto A, Hiramoto N, Yamasaki S, et al. Risk factors and predictive scoring system for post-transplant lymphoproliferative disorder after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25(7):1441\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"1544_CR2","doi-asserted-by":"publisher","first-page":"53.e1","DOI":"10.1016\/j.jtct.2021.09.021","volume":"28","author":"M Kinzel","year":"2022","unstructured":"Kinzel M, Dowhan M, Kalra A, et al. Risk Factors for the incidence of and the mortality due to post-transplant lymphoproliferative disorder after hematopoietic cell transplantation. Transplant Cell Ther. 2022;28(1):53.e1-e10.","journal-title":"Transplant Cell Ther."},{"issue":"6","key":"1544_CR3","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1093\/cid\/cit391","volume":"57","author":"J Styczynski","year":"2013","unstructured":"Styczynski J, Gil L, Tridello G, et al. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clin Infect Dis. 2013;57(6):794\u2013802.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1544_CR4","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1080\/10428194.2018.1474462","volume":"60","author":"S Romero","year":"2019","unstructured":"Romero S, Montoro J, Guinot M, et al. Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation. Leuk Lymphoma. 2019;60(1):142\u201350.","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"1544_CR5","doi-asserted-by":"publisher","first-page":"4530","DOI":"10.1182\/blood-2011-06-318220","volume":"118","author":"LB To","year":"2011","unstructured":"To LB, Levesque JP, Herbert KE. How I treat patients who mobilize hematopoietic stem cells poorly. Blood. 2011;118(17):4530\u201340.","journal-title":"Blood"},{"issue":"2","key":"1544_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12185-020-02890-1","volume":"112","author":"M Kuno","year":"2020","unstructured":"Kuno M, Ito A, Maeshima AM, et al. T-cell posttransplant lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Int J Hematol. 2020;112(2):193\u20139.","journal-title":"Int J Hematol"},{"issue":"4","key":"1544_CR7","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/cncr.24834","volume":"116","author":"R Cavaliere","year":"2010","unstructured":"Cavaliere R, Petroni G, Lopes MB, Schiff D. Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer. 2010;116(4):863\u201370.","journal-title":"Cancer"},{"issue":"6","key":"1544_CR8","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1111\/ajt.12211","volume":"13","author":"AM Evens","year":"2013","unstructured":"Evens AM, Choquet S, Kroll-Desrosiers AR, et al. Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era. Am J Transplant. 2013;13(6):1512\u201322.","journal-title":"Am J Transplant"},{"key":"1544_CR9","unstructured":"Green K, Munakomi S, Hogg JP. Central Nervous System Lymphoma. 2024 May 28. In: StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2024. PMID: 31424729."},{"key":"1544_CR10","doi-asserted-by":"publisher","first-page":"6042","DOI":"10.1038\/ncomms7042","volume":"6","author":"V Madan","year":"2015","unstructured":"Madan V, Kanojia D, Li J, et al. Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome. Nat Commun. 2015;6:6042.","journal-title":"Nat Commun"},{"key":"1544_CR11","doi-asserted-by":"crossref","unstructured":"Li W. The 5th Edition of the World Health Organization Classification of Hematolymphoid Tumors. In: Li W, editor. Leukemia [Internet]. Chapter 1. Brisbane: Exon Publications; 2022. PMID: 36395314.","DOI":"10.36255\/exon-publications-leukemia-who-5th-edition-hematolymphoid-tumors"},{"key":"1544_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"key":"1544_CR13","doi-asserted-by":"publisher","first-page":"1208028","DOI":"10.3389\/fonc.2023.1208028","volume":"13","author":"P L\u00fcckemeier","year":"2023","unstructured":"L\u00fcckemeier P, Radujkovic A, Holtick U, et al. Characterization and outcome of post-transplant lymphoproliferative disorders within a collaborative study. Front Oncol. 2023;13:1208028.","journal-title":"Front Oncol"},{"key":"1544_CR14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.12659\/AOT.914101","volume":"24","author":"CY Zhu","year":"2019","unstructured":"Zhu CY, Zhao SS, Wang XK, et al. Outcome of rituximab-based treatment for post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: a single-center experience. Ann Transplant. 2019;24:175\u201384.","journal-title":"Ann Transplant"},{"issue":"1","key":"1544_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s12185-012-1244-1","volume":"97","author":"DB Chen","year":"2013","unstructured":"Chen DB, Song QJ, Chen YX, Chen YH, Shen DH. Clinicopathologic spectrum and EBV status of post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2013;97(1):117\u201324.","journal-title":"Int J Hematol"},{"issue":"1","key":"1544_CR16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41409-023-02127-9","volume":"59","author":"G Soci\u00e9","year":"2024","unstructured":"Soci\u00e9 G, Barba P, Barlev A, et al. Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy. Bone Marrow Transplant. 2024;59(1):52\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"1544_CR17","doi-asserted-by":"publisher","first-page":"261.e1","DOI":"10.1016\/j.jtct.2020.12.019","volume":"27","author":"A Balaguer-Rosello","year":"2021","unstructured":"Balaguer-Rosello A, Pi\u00f1ana JL, Bataller L, et al. Central nervous system involvement in Epstein-Barr virus-related post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation. Transplant Cell Ther. 2021;27(3):261.e1-e7.","journal-title":"Transplant Cell Ther."},{"issue":"13","key":"1544_CR18","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1080\/10428194.2020.1797010","volume":"61","author":"MQ Salas","year":"2020","unstructured":"Salas MQ, Prem S, Remberger M, et al. High incidence but low mortality of EBV-reactivation and PTLD after alloHCT using ATG and PTCy for GVHD prophylaxis. Leuk Lymphoma. 2020;61(13):3198\u2013208.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"1544_CR19","doi-asserted-by":"publisher","first-page":"e1139274","DOI":"10.1080\/2162402X.2016.1139274","volume":"5","author":"X Jiang","year":"2016","unstructured":"Jiang X, Xu L, Zhang Y, et al. Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation. Oncoimmunology. 2016;5(5):e1139274.","journal-title":"Oncoimmunology"},{"key":"1544_CR20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.12659\/AOT.889683","volume":"19","author":"L Luo","year":"2014","unstructured":"Luo L, Zhang L, Cai B, et al. Post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation: a single-center experience. Ann Transplant. 2014;19:6\u201312.","journal-title":"Ann Transplant"},{"issue":"3","key":"1544_CR21","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3109\/10428194.2012.718342","volume":"54","author":"K Czyzewski","year":"2013","unstructured":"Czyzewski K, Styczynski J, Krenska A, et al. Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder. Leuk Lymphoma. 2013;54(3):503\u20136.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"1544_CR22","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/bmt.2014.298","volume":"50","author":"I Garc\u00eda-Cadenas","year":"2015","unstructured":"Garc\u00eda-Cadenas I, Castillo N, Martino R, et al. Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab. Bone Marrow Transplant. 2015;50(4):579\u201384.","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"1544_CR23","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1111\/ajt.13324","volume":"15","author":"MR Luskin","year":"2015","unstructured":"Luskin MR, Heil DS, Tan KS, et al. The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder. Am J Transplant. 2015;15(10):2665\u201373.","journal-title":"Am J Transplant"},{"issue":"20","key":"1544_CR24","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1182\/blood-2015-05-615872","volume":"126","author":"D Dierickx","year":"2015","unstructured":"Dierickx D, Tousseyn T, Gheysens O. How I treat posttransplant lymphoproliferative disorders. Blood. 2015;126(20):2274\u201383.","journal-title":"Blood"},{"issue":"1","key":"1544_CR25","doi-asserted-by":"publisher","first-page":"e0004","DOI":"10.5041\/RMMJ.10179","volume":"6","author":"K Perica","year":"2015","unstructured":"Perica K, Varela JC, Oelke M, Schneck J. Adoptive T cell immunotherapy for cancer. Rambam Maimonides Med J. 2015;6(1):e0004.","journal-title":"Rambam Maimonides Med J"},{"issue":"5","key":"1544_CR26","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1200\/JCO.20.01709","volume":"39","author":"HE Heslop","year":"2021","unstructured":"Heslop HE, Sharma S, Rooney CM. Adoptive T-cell therapy for epstein-barr virus-related lymphomas. J Clin Oncol. 2021;39(5):514\u201324.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1544_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5500\/wjt.v10.i2.29","volume":"10","author":"F Abbas","year":"2020","unstructured":"Abbas F, El Kossi M, Shaheen IS, Sharma A, Halawa A. Post-transplantation lymphoproliferative disorders: Current concepts and future therapeutic approaches. World J Transplant. 2020;10(2):29\u201346.","journal-title":"World J Transplant"},{"issue":"1","key":"1544_CR28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13244-019-0726-6","volume":"10","author":"ML White","year":"2019","unstructured":"White ML, Moore DW, Zhang Y, Mark KD, Greiner TC, Bierman PJ. Primary central nervous system post-transplant lymphoproliferative disorders: the spectrum of imaging appearances and differential. Insights Imaging. 2019;10(1):46.","journal-title":"Insights Imaging"},{"issue":"9","key":"1544_CR29","doi-asserted-by":"publisher","first-page":"e13652","DOI":"10.1111\/ctr.13652","volume":"33","author":"UD Allen","year":"2019","unstructured":"Allen UD, Preiksaitis JK. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: guidelines from the american society of transplantation infectious diseases community of practice. Clin Transplant. 2019;33(9):e13652.","journal-title":"Clin Transplant"},{"issue":"2","key":"1544_CR30","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S1470-2045(11)70300-X","volume":"13","author":"R Trappe","year":"2012","unstructured":"Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol. 2012;13(2):196\u2013206.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1544_CR31","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1097\/01.TP.0000079253.06061.52","volume":"76","author":"R Snanoudj","year":"2003","unstructured":"Snanoudj R, Durrbach A, Leblond V, et al. Primary brain lymphomas after kidney transplantation: presentation and outcome. Transplantation. 2003;76(6):930\u20137.","journal-title":"Transplantation"},{"issue":"8","key":"1544_CR32","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1007\/s00277-021-04548-2","volume":"100","author":"H Zimmermann","year":"2021","unstructured":"Zimmermann H, Nitsche M, Pott C, et al. Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry. Ann Hematol. 2021;100(8):2043\u201350.","journal-title":"Ann Hematol"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-024-01544-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13000-024-01544-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-024-01544-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T01:03:25Z","timestamp":1725757405000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-024-01544-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,7]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1544"],"URL":"https:\/\/doi.org\/10.1186\/s13000-024-01544-8","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,7]]},"assertion":[{"value":"20 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study was approved by the ethics committees of Qilu Hospital of Shandong University according to the Helsinki Principles. Written informed consent was obtained from the family members of the patient for the publication of the clinical information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"122"}}